I aim to encapsulate Cabozantinib within nanoliposome. However, the existence of two drug formulations, free base and s-malate, and the lack of clarity in the literature regarding which form has been used in previous studies pose a significant challenge in selecting the appropriate formulation for my research.
I would be grateful if any researcher with relevant experience could provide guidance.
Hi Mohsen Soltanshahi ,
Cabozantinib is a highly hydrophobic drug and the different forms of the drug can improve its solubility in aqueous environments to a certain degree. For example, the s-malate form (and hydrochloride form) could display an slightly enhanced solubility in water compared to the free base form of cabozantinib. These salt forms can help the crystallization of the drug and therefore its pharmaceutical formulation. The s-malate form is what patients get, I believe, so I would recommend it for a better translation of your research to clinical outcome.
Despite slight differences in water solubility, the free base and s-malate forms of the drug are fairly hydrophobic which is why the oral route of administration is preferred. Both forms can be used for liposomal formulation, depending of the characteristics of your liposomes.
Check out this manuscript on the topic
Article Dual‐Targeting Nanoliposome Improves Proinflammatory Immunom...
Although the cabozantinib form is not specified in the materials, you can perhaps reach out to the authors to find out more.
Additionally, this patent outlines a liposomal preparation of cabozantinib malate
https://patents.google.com/patent/CN115844826A/en
Hope this helps!
- Badges
- Science topic